Objective: To investigate the effect of cell proliferation in human breast cancer cells (MDA-MB 435), which has non-receptor of estrogen (Er), induced by beta-ionone. MDA-MB 435 cells were treated with different beta-ionone concentrations (25, 50, 100 and 200 micromol/L), with a negative control.
Methods: Such as curve of cell growth, cellular mitosis, the clone formatting, DNA synthesis, and western blotting for protein of PCNA and MAPK pathway were employed.
Results: beta-ionone inhibited the cell proliferation, cellular mitosis, clone formatting and DNA synthesis and reduced expression of PCNA protein in MDA-MB 435 cells. The inhibitory frequency (IF) showed a dose-dependent responses as the concentrations of beta-ionone increased. Seven days after treatment with various concentrations of beta-ionone, as mentioned above, the inhibition rates were 45.65%, 71.24%, 81.53%, and 84.93%, respectively. Its IC50 value was 42.0 micromol/L for MDA-MB 435 cells. The IF from cellular mitosis of MDA-MB 435 cells treated by beta-ionone were - 34.57%-58.857% at 24 h and - 30.05%-75.12% at 48 h, from the clone formatting assay, - 4.44%-63.79% at 24 h and 6.42%-95.55% at 48 h, from DNA synthesis, 17.00%-57.56% at 24h and 62.25%-78.35% at 48 h. The further study was found that beta-ionone inhibited the expression of PCNA which to be related to cell cycle and reduced ERK, MEK-1 proteins expression and promoted the expression of JNK and MKP-1 proteins related to MAPK pathway in MDA-MB 435 cells.
Conclusion: beta-ionone could inhibit MDA-MB 435 cells proliferation by regulating MAPKs pathway. It may be one of the effects of beta-ionone in anticancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Facile and Promising Delivery Platform for siRNA to Solid Tumors.
Molecules
November 2024
Department of Pathology, University of Maryland School of Medicine, 10 S. Pine St., Baltimore, MD 21201, USA.
Over 20 years have passed since siRNA was brought to the public's attention. Silencing genes with siRNA has been used for various purposes, from creating pest-resistant plants to treating human diseases. In the last six years, several siRNA therapies have been approved by the FDA, which solely target disease-inducing proteins in the liver.
View Article and Find Full Text PDFRadioiodinated Nanobody immunoPET probe for in vivo detection of CD147 in pan-cancer.
Eur J Nucl Med Mol Imaging
November 2024
State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Peking University Cancer Hospital & Institute, Beijing, 100142, China.
Background: To develop the extracellular matrix metalloproteinase inducer (CD147)-targeting therapeutic strategies, accurate detection of CD147 expression in tumors is crucial. Owing to their relatively low molecular weights and high affinities, nanobodies (Nbs) may be powerful candidates for cancer diagnosis and therapy. In this study, we developed a novel CD147-targeted nanobody radiotracer, [I]I-NB147, which provides guidance for the noninvasive detection of CD147-overexpressing cancers.
View Article and Find Full Text PDFDesign of novel potent selective survivin inhibitors using 2D-QSAR modeling, molecular docking, molecular dynamics, and ADMET properties of new MX-106 hydroxyquinoline scaffold derivatives.
Heliyon
October 2024
LIMAS Laboratory, Faculty of Sciences Dhar El Mahraz, Sidi Mohamed Ben Abdellah University, Fez, Morocco.
Article Synopsis
- The study focuses on creating new inhibitors for survivin (BIRC5), an important protein in cancer cell regulation, as a new strategy for cancer treatment.
- Researchers designed nine novel compounds based on previous work with MX-106, demonstrating stronger inhibitory effects on breast cancer cell growth in lab tests.
- Advanced techniques like molecular modeling and assessment of drug-like properties (ADMET) were used to ensure these new compounds (Pred1-Pred9) are viable candidates for cancer therapy targeting survivin.
The Cytochalasins and Polyketides from a Mangrove Endophytic Fungus QYF.
Mar Drugs
September 2024
School of Chemistry, Sun Yat-sen University, Guangzhou 510006, China.
Twelve compounds, including four undescribed cytochalasins, xylariachalasins A-D (-), four undescribed polyketides (-), and four known cytochalasins (-), were isolated from the mangrove endophytic fungus QYF. Their structures and absolute configurations were established by extensive spectroscopic analyses (1D and 2D NMR, HRESIMS), electronic circular dichroism (ECD) calculations, C NMR calculation and DP4+ analysis, single-crystal X-ray diffraction, and the modified Mosher ester method. Compounds and are rare cytochalasin hydroperoxides.
View Article and Find Full Text PDFIsolation and chemical characterization of secondary metabolites from and their antimicrobial and cytotoxic activities.
Nat Prod Res
August 2024
National Center for Natural Products Research, School of Pharmacy, University of Mississippi, Oxford, MS, USA.
Phytochemical study of whole plant led to isolation and structural characterisation of six known compounds including lupeol (), lupenone (), -sitosterol 3---glucopyranoside (), dunalianoside D (), 3,5-di--caffeoylquinic acid (), and tachioside (). Compounds (, and ) were isolated for the first time. The structures of the isolated compounds were elucidated using different spectroscopic analyses such as H,C, and DEPT NMR analyses, besides HR-ESI-MS analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!